Yes, Zepbound is FDA approved for weight loss. The U.S. Food and Drug Administration approved it on November 8, 2023, specifically for chronic weight management in adults with obesity or overweight who have at least one weight-related health condition. It was one of the most anticipated weight loss approvals in years, largely because clinical trial results showed participants losing up to 20.9% of their body weight.
What the FDA Approval Covers
The FDA approved Zepbound (tirzepatide) as an add-on to a reduced-calorie diet and increased physical activity. It’s indicated for adults who meet one of two criteria: a BMI of 30 or greater, which qualifies as obesity, or a BMI of 27 or greater with at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease.
This means Zepbound is not approved for people who simply want to lose a few pounds. The FDA specifically framed it as a treatment for chronic weight management, recognizing obesity as an ongoing medical condition rather than a short-term problem to fix.
Zepbound and Mounjaro Are the Same Drug
If the name tirzepatide sounds familiar, that’s because it’s also sold as Mounjaro for type 2 diabetes. Zepbound and Mounjaro are the exact same medication at the same strengths. Eli Lilly gave the drug a second brand name when it received the weight management approval. This is a common pharmaceutical practice in the U.S., though not universal. In Europe, the European Medicines Agency simply added the weight loss indication to Mounjaro without requiring a new name.
How Zepbound Works
Zepbound targets two hormone pathways involved in appetite and metabolism. Most people are familiar with GLP-1 drugs like Ozempic and Wegovy, which activate a single gut hormone receptor to slow digestion and reduce hunger. Zepbound activates that same receptor but also activates a second one, called the GIP receptor. This dual action is what sets it apart.
The GIP receptor is found in fat tissue and in areas of the brain that regulate appetite and energy balance. Research shows that activating both pathways together produces a stronger effect on hunger suppression than targeting GLP-1 alone. The drug also influences how your body signals fullness after eating, which helps reduce overall calorie intake without the constant feeling of fighting cravings.
How Much Weight People Lose
The landmark clinical trial, known as SURMOUNT-1, tested three doses of Zepbound against a placebo over 72 weeks. The results were striking. Participants on the lowest maintenance dose (5 mg) lost an average of 15% of their body weight. Those on the 10 mg dose lost 19.5%, and the highest dose (15 mg) produced an average loss of 20.9%. For context, that means a person weighing 250 pounds on the highest dose would lose roughly 52 pounds over about a year and a half.
These are averages, so some people lost more and some lost less. But even the lowest dose outperformed most other weight loss medications on the market at the time of approval.
How the Dosing Schedule Works
Zepbound is a once-weekly injection you give yourself under the skin, typically in the abdomen, thigh, or upper arm. Everyone starts at the same place: 2.5 mg per week for the first four weeks. This starting dose is not a treatment dose. It’s meant to let your body adjust and minimize side effects.
After four weeks, the dose increases to 5 mg. From there, your prescriber can increase it in 2.5 mg steps, with at least four weeks between each increase, up to a maximum of 15 mg per week. The maintenance dose that works for you could be 5 mg, 10 mg, or 15 mg, depending on how your body responds and what you can tolerate.
Common Side Effects
Gastrointestinal issues are by far the most common side effects. In clinical trials, about 56% of people taking Zepbound at any dose experienced some form of stomach-related side effect, compared to 30% on placebo. The most frequently reported problems were nausea (25-29% depending on dose), diarrhea (19-23%), constipation (11-17%), and vomiting (8-13%). Stomach pain, indigestion, and acid reflux also occurred more often than with placebo.
The good news is that most nausea, vomiting, and diarrhea occurred during the dose escalation period and tapered off over time. This is one reason the gradual titration schedule exists. Still, between 1.9% and 4.3% of participants discontinued treatment because of GI side effects, with higher dropout rates at higher doses.
Important Safety Warnings
Zepbound carries a boxed warning, the most serious type of FDA warning, about thyroid tumors. In animal studies, tirzepatide caused thyroid C-cell tumors in rats. Whether this translates to a risk in humans is unknown, but as a precaution, Zepbound is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. It’s also contraindicated for anyone with a known serious allergy to tirzepatide.
What It Costs
Zepbound’s cost depends heavily on your insurance situation. If you have commercial insurance that covers it, Eli Lilly offers a savings card that can bring your copay down to as little as $25 per month, with a maximum annual savings of $1,300. If your commercial insurance doesn’t cover Zepbound, you can still use a savings program to pay as low as $499 per month for the single-dose pen, or between $299 and $449 per month for the multi-use KwikPen depending on your dose.
For people paying entirely out of pocket, the KwikPen list prices range from $299 per month at the 2.5 mg starting dose to $699 per month at the 10 mg, 12.5 mg, or 15 mg doses. These savings programs are not available to people on government insurance like Medicare, Medicaid, or Tricare. The current savings card program runs through December 31, 2026.
Who Qualifies
Meeting the BMI criteria is the starting point, but getting a prescription also depends on your prescriber’s assessment and your insurance plan’s requirements. Many insurers impose their own conditions before covering weight loss medications, such as requiring documented previous weight loss attempts or proof of specific comorbidities. The BMI thresholds (30+ or 27+ with a related condition) are the FDA’s criteria for appropriate use, but your insurer may interpret coverage differently.
BMI itself has well-known limitations as a measure of health, but it remains the standard metric that the FDA and insurance companies use when defining eligibility for weight management medications.